MLTX MoonLake Immunotherapeutics Loading...

Loading chart...
Top Calls

No data yet

Price change since each call, adjusted for long/short direction. Results calculated:

Feed
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...
0 selected
All Content✓
Source feeds
Buzzberg Top 50 ✓
All market capsNo capitalization filter✓
200 B and aboveMega✓
10 B to 200 BLarge✓
2 B to 10 BMid✓
0 to 2 BSmall✓
Custom
Enter market cap range in B USD
Time Author Thesis Company / ticker Signal Since call Position Source
16:42
Jun 22
A May MD
Short MLTX as the core efficacy differentiation thesis.
Short MLTX as the core efficacy differentiation thesis — smaller molecule size conferring superior efficacy vs. Bimzelx — has been empirically invalidated by Phase 3 results (one trial missed, the other failed to beat the comparator), removing the primary bull case.
MLTX MoonLake Immunotherapeutics Short 1ST — —
13:14
Jan 11
A May MD
Recalls bearish MLTX views during decline
The author recalls sharing bearish views on MLTX while it fell from $60, without giving a current MLTX-specific rationale. They say they have never told anyone to buy, sell or short stocks and disclose no position.
MLTX MoonLake Immunotherapeutics Avoid — —

About MLTX Investor Commentary

Across the available history and selected sources, Buzzberg tracks MLTX (MoonLake Immunotherapeutics) across 2 sources: 0 bullish vs 1 bearish calls from 2 authors. Historical directional balance: -11% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 9 total trade ideas tracked. Latest voices: A May MD.